The Food and Drug Administration recently announced in the Federal Register that it has released its draft "Blueprint for Prescriber Continuing Education Program.” The blueprint is designed to guide continuing medical education providers as they develop materials to use to train prescribers of long-acting and extended release opioids under these products’ required risk evaluation and mitigation strategy, or REMS. This blueprint’s impending arrival was a hot topic at this fall’s American ...

Register for Complete Access (Valid Email Required)

By registering on MeetingsNet now, you'll not only unlock thePrinter-friendly, you'll also gain access to exclusive premium content.

Already registered? here.